Metaphore Biotechnologies seeks to mimic nature with $50M for autoimmune, immunology drugs out of Flagship
Flagship Pioneering has churned out another biotech startup that taps into nature’s seemingly endless supply of insights and, like many new life sciences companies, is equipping its lab with machine learning to fine-tune its platform.
After years behind the scenes at the biotech incubator, Metaphore Biotechnologies is out with an initial $50 million from Flagship to mimic nature and go after whatever targets it sees fit. The lofty goal matches the vision set forth by other Flagship startups initially led by Metaphore CEO Lovisa Afzelius; these include Apriori Bio and Alltrna.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.